The new CEO of Sanofi, the French drug giant, believes that its drug Dupixent, for the treatment of severe rashes and asthma, could surpass $10 billion in annual sales.

Paul Hudson, who became CEO in September, said Monday that growing sales of Dupixent, which is sold with the U.S. biotech Regeneron, would be Sanofi’s top priority. It “has the chance to be one of the most successful medicines in the history of the industry, built on the back of patients with huge unmet need who are living horribly debilitated lives, who can reach, in many cases, normal lives,” Hudson said.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy